Key result
Two doses of mRNA-1273 or BNT162b2 vaccine in people with HIV led to 100% seroconversion and no severe adverse events.
Why the study?
The safety and serological response after two doses of mRNA-based SARS-CoV-2 vaccination needed to be evaluated in people with HIV.
Do two doses of mRNA-based SARS-CoV-2 vaccines produce a safe and effective serological response in people with HIV?
Comparison
mRNA-1273 or BNT162b2 vaccine
Follow-up
4 weeks after the second dose
Loading...
Supports mRNA vaccine use in HIV on ART; hypothesis-generating for durability and clinical protection.
Cohort (n=100)
Do two doses of mRNA-based SARS-CoV-2 vaccines produce a safe and effective serological response in people with HIV?
Two doses of mRNA-based SARS-CoV-2 vaccines are safe and highly immunogenic in people with HIV on effective antiretroviral therapy.
A 2022 study conducted a cohort in HIV (n=100). mRNA-1273 or BNT162b2 vaccine was evaluated on Seroconversion (antibody concentration ≥33.8 BAU/ml). Two doses of mRNA-1273 or BNT162b2 vaccine in people with HIV led to 100% seroconversion and no severe adverse events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: